Member Info for bunsenburner123

Interesting week coming up chaps

Also - research #SBDS. Can’t see it staying this cheap with Apple as one of their customers, over £10m revenues and the board saying end of Q2 cash generative. £4m market cap 👀

Just read this - too many of you really do not understand what MPAL are trying or rather, are achieving…:

1. It assumes costs stay at £7m while gross profit scales linearly

Management isn’t talking about a conventional retail business.

They’re talking about:

* robotic dispensing,

* NHS prescription volume,

* care homes,

* GLP-1 clinic.

The bull argument is that once the infrastructure is in place, additional volume may carry very high incremental margins.

For example:

If revenue goes:

* £5m → £10m → £15m → £20m

the gross margin may improve from:

* 34% → 36% → 38% → 40%

rather than staying fixed.

If margins reach 40%, breakeven revenue falls materially.

2. It ignores management’s own breakeven metric

This is the biggest issue.

Management didn’t say:

“We need £20m revenue.”

They said:

“Pharmacy-level EBITDA breakeven at 80,000 items per month.”

That suggests management is measuring the business operationally rather than purely by revenue.

And importantly:

The acquired Runcorn pharmacy historically dispensed 994,366 items in 2024.

That’s roughly 83,000 items per month.

So management is effectively saying:

“One of the assets we’ve just bought has historically operated above the level we believe is needed for pharmacy-level breakeven.”

That doesn’t prove they’re right, but it does mean the £20m revenue calculation may not capture the operational leverage in the model.

Diesels right - this is not a knew drug conjugate. Chances of success are increased dramatically

Couple with significant grant funding

Let’s see, at this cap it’s the best value Pharma stock I’ve ever seen

Valued like it’s pre clinical

It’s P2 and can license pre P3 or completely bypass P3 since it’s registration grade - it’s really needed and there’s currently very limited if at all medication currently

Position accordingly

Lol yup. Some people just don’t get it

Key thing is this - watch the interviews. Jason clearly states we can increase output exponentially without much of an increase of costs

Everything’s in place, robots do the work not humans

Quite a few of you are looking at this through the lens of a traditional style of business

Traditional this is not. This is an AI robotics, super scalable, super growth… with only a very small increase of costs. It’s essentially a futuristic sector

Position accordingly

Guys I just posted this on the HEMO board but thought I’d share here as well, apologies if not appreciated but if you get time, research CRTX this weekend

Market cap sub £10m. £2.8m cash. ‘Significant grant funding’ - company did the placing to help secure it

It’s a P2 registration grade in human cancer trial, potentially being able to license before or bypass P3. Value IMO is potentially insane. Not a quick flip though likely a medium term hold IMO

Market cap at 15p £11.9m

When we hit 15p we should have around £2.5m cash. No debt, a large non dilutive grant and be a P2 in human, registration grade cancer trial.

That is completely absurd

Will still be the cheapest P2 there’s ever been. Tell me another P2 Pharma at that price??

Ok so market cap at 10p is?

My guess is a plethora of news flow leading up to MPAL selling the fat pill. They have direct links with some of the world largest pharmaceutical companies to sell this. Links with the NHS. Robotic dispensing. Growth off the charts. Watch this soar in the coming weeks and months. Very bullish

That numbers at the bottom

Of the placing RNS

So I assume it’s the the total but not including the extra £240,000

Following the issue of the Firm Placing Shares, the total issued share capital of the Company will consist of 54,235,266 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company will be 54,235,266

Anyone know the reason for the rise here today? Is it gearing up for another run?

My money is on SBDS currently though - learning that Apple is one of their customers. Interesting to say the least. £4m cap with £10m+ revenues and BOD saying cash generative end of Q2. One to keep an eye on as is CPX 👀

Also, look at the volume on results. Very unusual. Just wait until we get some proper rampy news. Epic feeling here chaps. Still valued at placing price 👀

Great shout Smkr. People would do well to look into Jason - he’s basically well known for being a pioneer of new tech and sectors, making big bank and moving on.

This could well be his biggest play yet 👀

One hub could do 80,000 on historic capabilities- A MONTH

The growth we could be about to witness could be the greatest on the small cap markets we’ve ever seen

Management has stated that pharmacy-level EBITDA breakeven is expected at around 80,000 prescription items per month. Yet the recently acquired Runcorn pharmacy historically dispensed 994,366 prescription items in 2024 — equivalent to more than 82,000 items per month on average. In other words, a single acquired dispensing hub has previously operated above the volume threshold management says is required for breakeven. If MedPal can successfully reactivate that patient base while continuing to grow Swaffham and MedPal.clinic, the gap between today’s volumes and profitability may be considerably smaller than many investors assume.

Ooooo what’s going on here then?? 👀

SBDS my other large holding. Well worth researching

I don’t think that’s the intention. The ceo wants to delist take it private but ultimately I don’t think he will. What happens next??

NANO isn’t my most bullish share - most bullish on SBDS: 🌍 Client wins and partnerships continue to stack up, with references across recent updates including Apple, Visa, Vodafone, BMW, Boots, Universal Music, Sky Bet, Thomson Reuters, Rover, Mars and major international airline. For a business valued at only around £4m, that’s a remarkably strong list of commercial names.

NANO higher risk but if this vote falls through there’s a bag in it for sure

All in my opinion of course, GLA

🚀 For a company sitting at roughly a £4m market cap, the recent progress at Silverbullet looks increasingly hard to ignore.

📈 Revenue grew to £9.4m in FY2024, with proprietary 4D AI revenues rising 25% to £3.5m. Then in Q1 2026 the company reported revenue growth accelerating to 22% year-on-year, while also stating it achieved positive EBITDA for the first time in its history.

🌍 Client wins and partnerships continue to stack up, with references across recent updates including Apple, Visa, Vodafone, BMW, Boots, Universal Music, Sky Bet, Thomson Reuters, Rover, Mars and major international airline and APAC marketing relationships. For a business valued at only around £4m, that’s a remarkably strong list of commercial names.

🤖 The company has also integrated with major advertising ecosystem platforms including The Trade Desk and a global DSP owned by a Nasdaq-listed technology company generating around $2bn in annual revenue. Management continues to position 4D AI as a privacy-first contextual advertising solution as AI increasingly reshapes digital marketing.

💰 The biggest recent development may be financial. After restructuring its debt and extending maturities, management stated in its Q1 2026 update that the company was EBITDA positive, with profitability improving by around £700k year-on-year. More importantly, the Board said it expects the business to become cash-flow positive from the end of Q2 onwards.

👔 The appointment of former Twitter UK Managing Director and senior Google/YouTube executive Dara Nasr adds further credibility to the commercial growth story. His background in scaling large digital advertising businesses appears highly aligned with Silverbullet’s ambitions around AI, media and global partnerships.

⚡ At a valuation of only around £4m, the market is still clearly pricing in balance-sheet risk and execution risk. But if the company genuinely delivers sustained EBITDA profitability, cash generation and continued growth, the gap between valuation and operational progress could become increasingly difficult for the market to justify

How many companies can boast Apple as their client/customer win and only have a cap of £4m?

Few new buyers realising this is probably the cheapest share on the market by a factor of 10